Clinical trials: Adamantinous Craniopharyngioma, active
Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2.
- Trial name
- NCT05286788
- Testing
- Binimetinib Oral Tablet [Mektovi]
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 38 people
- Sponsor
- Nationwide Children's Hospital